Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.61 |
| ▸ | ACE | P12821 | 5/20 | 0.61 |
| ▸ | CPA1 | P15085 | 2/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | FCER2 | P06734 | 3/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576006 | 1.00 | MME (0.61) | MMEACECPA1ACE2PTPN1 | |
| SCHEMBL29898367 | 0.93 | MME (0.67) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL31264142 | 0.93 | MME (0.66) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL29494074 | 0.93 | MME (0.66) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL30519188 | 0.89 | OPRD1 (0.65) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL30305683 | 0.89 | MME (0.57) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29386041 | 0.87 | MME (0.60) | MMEACECPA1ACE2PTPN1 | |
| SCHEMBL15342313 | 0.87 | MME (0.60) | MMEACECPA1ACE2PTPN1 | |
| SCHEMBL31215087 | 0.85 | MME (0.57) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL31215105 | 0.85 | MME (0.57) | MMEACECPA1ACE2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-113423430-B | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117042808-A | FAP activated serum half-life extending therapeutic conjugates | 阿瓦克塔生命科学有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116963781-A | Enzyme activated serum half-life extending therapeutic conjugates | 阿瓦克塔生命科学有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110099682-B | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115505028-A | Branched polyethylene glycol linker and application thereof | 辽宁键凯科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115300640-A | Novel linkers and their use for specific coupling of drugs and biomolecules | 杭州多禧生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220153802-A1 | A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153802-A1 | A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | LPXN, GNRHR, CYP19A1 | MME 1500/4885ACE 917/4885CPA1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.